| Literature DB >> 31048404 |
Matteo Tardelli1, Francesca V Bruschi1, Thierry Claudel1, Claudia D Fuchs1, Nicole Auer1, Victoria Kunczer1, Tatjana Stojakovic2, Hubert Scharnagl3, Aida Habib4,5, Gernot F Grabner6, Robert Zimmermann6, Sophie Lotersztajn4, Michael Trauner7.
Abstract
Monoacylglycerol lipase (MGL) is the rate-limiting enzyme in the degradation of monoacylglycerols. To examine the role of MGL in hepatic steatosis, WT and MGL KO (MGL-/-) mice were challenged with a Western diet (WD) over 12 weeks. Lipid metabolism, inflammation, and fibrosis were assessed by serum biochemistry, histology, and gene-expression profiling of liver and adipose depots. Intestinal fat absorption was measured by gas chromatography. Primary adipocyte and 3T3-L1 cells were analyzed by flow cytometry and Western blot. Human hepatocytes were treated with MGL inhibitor JZL184. The absence of MGL protected mice from hepatic steatosis by repressing key lipogenic enzymes in liver (Srebp1c, Pparγ2, and diacylglycerol O-acyltransferase 1), while promoting FA oxidation. Liver inflammation was diminished in MGL-/- mice fed a WD, as evidenced by diminished epidermal growth factor-like module-containing mucin-like hormone receptor-like 1 (F4/80) staining and C-C motif chemokine ligand 2 gene expression, whereas fibrosis remained unchanged. Absence of MGL promoted fat storage in gonadal white adipose tissue (gWAT) with increased lipogenesis and unchanged lipolysis, diminished inflammation in gWAT, and subcutaneous AT. Intestinal fat malabsorption prevented ectopic lipid accumulation in livers of MGL-/- mice fed a WD. In vitro experiments demonstrated increased adipocyte size/lipid content driven by PPARγ. In conclusion, our data uncover that MGL deletion improves some aspects of nonalcoholic fatty liver disease by promoting lipid storage in gWAT and fat malabsorption.Entities:
Keywords: adipocyte; adipocytes/obesity; fatty acid/metabolism; lipolysis and fatty acid metabolism; monoacylglycerol lipase; nonalcoholic fatty liver disease; nuclear receptors/peroxisome proliferator-activated receptor; obesity
Mesh:
Substances:
Year: 2019 PMID: 31048404 PMCID: PMC6602129 DOI: 10.1194/jlr.M093369
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922